Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

New VPAG scheme to save NHS £14 billion

New VPAG scheme to save NHS £14 billion

The level of annual allowed growth in sales of branded medicines will double from two per cent per year in 2024 to four per cent per year by 2027  

The Department of Health and Social Care (DHSC), NHS England and the Association of the British Pharmaceutical Industry (ABPI) have reached an agreement on the 2024 voluntary scheme for branded medicines pricing, access and growth (VPAG).


The landmark deal will save the NHS £14 billion over 5 years in medicines costs, boost the nation’s health, and support research investment.

The new VPAG scheme, which will be a non-contractual voluntary agreement between DHSC and ABPI, will run for 5 years from 1 January 2024 until 31 December 2028.

It will double the annual allowed growth of sales of branded medicines from two per cent per year in 2024 to four per cent per year by 2027.

Under the new agreement, the pharmaceutical industry will also invest £400 million over 5 years through the Life Sciences Investment Programme to drive forward UK innovation, sustainability and growth.

Commenting on the deal, Health Secretary Victoria Atkins said: “Millions of NHS patients will benefit from this momentous, UK-wide agreement.

“Not only will it save the health service billions of pounds every year, it will allow more patients to quickly access the latest life-saving medicines and treatments.

“This deal will also ensure the UK remains a world leader in driving forward innovative healthcare while boosting our economy, with hundreds of millions of pounds invested in vital research, clinical trials and manufacturing,” she added.

DHSC, NHSE, and ABPI  also agreed to introduce a new affordability mechanism for older medicines under the new scheme.

From next year, older medicines which have not seen price reductions will have to pay a top-up rate of up to 25 per cent in addition to the older medicines base rate of 10 per cent.

The income from this mechanism will be used to support lower payment rates for more innovative medicines.

Robert Kettell, NHS England’s Director of Medicines Negotiation and Managed Access, who led day-to-day negotiations, said: “This 5-year agreement will enable NHS England to build on our track record of securing innovative, life-changing treatments for millions of patients across the country at a fair price for taxpayers.

“In leading the negotiations, I was clear that any deal had to enable patients to have rapid access to cutting-edge medicines and incentivise the medical research that will provide the treatments of tomorrow. I am confident this agreement delivers these aims,” he added.

The pharmaceutical industry supports the agreement, despite its restrictions, as it “provides important support for patients and the NHS and commits to giving them access to the transformative treatments they need.”

Richard Torbett, Chief Executive at the ABPI, commented: “Allowing the sector to grow faster than it has under the previous scheme should increase the UK’s international competitiveness over time. Importantly, it also recognises the pressing need to invest more in building NHS capacity to partner with industry on science and research to support innovation and economic growth.”

More For You

A woman using a period tracker app

Cambridge University academics have flagged concerns over the safety of period tracker apps

Pic credit: iStock

Users of period tracking apps face privacy, safety risk, say experts

The report said the apps provide a "gold mine" of data for consumer profiling and warn that in the wrong hands it could pose a safety risk

CAMBRIDGE UNIVERSITY academics have flagged concerns over the safety of period tracker apps and warned that the women using them could face privacy and safety risks.

Keep ReadingShow less
Patients to get test results via NHS app

An investment of £50m has been made to upgrade the NHS app

Patients to get test results via NHS app

Millions of patients will now be able to access test results and get appointment reminders on their smartphones as the government tries to position the NHS app as the default mode of communication and steer away from traditional methods like letters.

An investment of £50m has been made to upgrade the NHS app and the health service hopes to save £200m over the next three years.

Keep ReadingShow less
Health minister assures House of Lords on measures to tackle UK-wide Creon drug shortage

Baroness Merron

Government taking steps to mitigate shortage of cancer drug Creon

Baroness Merron on Monday (9) assured the House of Lords that the government is taking measures to mitigate the shortage of pancreatic cancer drug Creon across the country.

Raising the issue, Baroness Margaret Ritchie wanted to know about the steps being taken by the government to ease the misery of patients suffering from pancreatic cancer.

Keep ReadingShow less
Janet Morrison: "Eventual outcome of spending review needs to tackle pharmacy underfunding"

Janet Morrison

Janet Morrison: "Eventual outcome of spending review needs to tackle pharmacy underfunding"

Community Pharmacy England (CPE) chief executive Janet Morrison has welcomed chancellor Rachel Reeves announcement today that day-to-day spending on the NHS will increase by £29bn a year but insisted that it must reflect in securing the future of pharmacy.

Reeves also revealed that the government will be increasing the NHS technology budget by almost 50 per cent, with £10bn of investment to "bring our analogue health system into the digital age, including through the NHS app".

Keep ReadingShow less
Lynsey Cleland named GPhC chief standards officer

Lynsey Cleland

Pic credit: X

Lynsey Cleland named GPhC chief standards officer

The General Pharmaceutical Council (GPhC) has brought back Lynsey Cleland to lead on a number of important departments in the role of chief standards officer.

Cleland had previously held a number of senior positions at GPhC, including director of Scotland.

Keep ReadingShow less